Medicines in the making
Our founding team has worked extensively in cancer R&D. Our pipeline will always reflect this hard-won experience. But cancer drug discovery is a great teacher for working on difficult problems in other disease areas. We sometimes pursue non-cancer programs – such as autoimmune and neurological diseases – when we believe we have a unique advantage.
Programs designed to maximize patient impact
Lymphoma
TLN-121
BCL6 is a naturally occurring protein that some lymphoma cells exploit to turn off genes that could get in the way of their mutating, proliferating and surviving as cancer cells. We designed TLN-121 to remove BCL6 from the cell while avoiding other targets that could cause toxicity. We believe this drug design choice will give TLN-121 the best chance at being used in combination with other medicines useful in the treatment of lymphoma.
TLN-254
EZH2 is a naturally occurring protein that helps cells regulate which genes are translated into proteins. It is overexpressed and even mutated in many cancers. We in-licensed TLN-254 after it had already undergone Phase 2 testing in patients with refractory lymphoma. We believe EZH2 inhibitors are an under-explored drug class that could have additional uses in making other anti-cancer medicines better.
Solid Tumors
TLN-372
Approximately 1 in 4 adult cancers harbors an alteration in the KRAS protein. There are FDA-approved medicines for G12C cancers, a subset of KRAS tumors, but other subsets have no targeted treatments. Our chemists went “back to basics” to innovate rather than follow, producing a compound that promises to provide deep and constant pan-KRAS target inhibition.
Target
KRAS
Diseases
Solid tumors
Phase
1
About Treeline’s Investigational Medicines
We are focused on developing and carefully studying new therapies with the hope of helping patients. Right now, our therapies are investigational, which means they have not yet been approved as safe and effective by the U.S. Food and Drug Administration (FDA) or other health authorities. Currently, patients can access these investigational therapies only by taking part in one of our clinical trials.
To learn more about these investigational therapies and how to access them, please talk with your provider or visit ClinicalTrials.Gov.